Dexcom Inc. Stock
Price
Target price
€104.90
€104.90
2.430%
2.48
2.430%
€125.00
22:26 / Tradegate
WKN: A0D9T1 / Symbol: DXCM / Name: DexCom / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Dexcom Inc. Stock
Dexcom Inc. gained 2.430% today.
The stock is an absolute favorite of our community with 23 Buy predictions and no Sell predictions.
With a target price of 125 € there is a slightly positive potential of 19.16% for Dexcom Inc. compared to the current price of 104.9 €.
Our community identified positive and negative aspects for Dexcom Inc. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Dexcom Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Dexcom Inc. in the next few years
Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dexcom Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dexcom Inc. | 2.430% | -4.540% | -4.718% | -12.470% | -8.717% | 12.369% | 224.496% |
| Dentsply Sirona Inc. | -0.570% | -3.129% | -10.051% | -36.852% | -28.807% | -57.448% | -55.874% |
| Zimmer Holdings | 0.410% | -2.495% | -5.125% | -24.738% | -10.473% | -27.375% | -3.451% |
| Teleflex Inc. | -0.510% | 1.031% | -1.010% | -10.909% | -13.274% | -42.353% | - |
Comments
As a user who has been following the news and analyses, I have a positive outlook on Dexcom Inc. (DXCM). The company's recent partnership expansion in the Netherlands to offer an easier diabetes management experience with its G6 CGM system is a promising development. This aligns with Dexcom's strategic focus on expanding its reach and improving the lives of individuals with diabetes. Additionally, the upcoming Q2 2024 earnings release and conference call is an opportunity for the company to showcase its performance and future plans. While the recent insider selling by the EVP Chief Legal Officer may raise some eyebrows, it's important to consider the bigger picture. Overall, Dexcom's strong market position, innovative products, and growth prospects make it an appealing investment option. I believe the stock has the potential to reach a target price of $125.00 in the near future.
Show more
Dexcom's innovative continuous glucose monitoring (CGM) technology has been making waves in the healthcare industry. As a user, I'm impressed by the company's latest advancements and its ability to deliver cutting-edge solutions for diabetes management. The recent news about Dexcom's G6 CGM system being combined with automated insulin delivery (AID) in the Netherlands is a prime example of how the company is driving innovation and improving the lives of individuals with diabetes. Additionally, the positive clinical data showcased at the ADA 2024 conference further strengthens my confidence in Dexcom's products and their ability to benefit people with type 2 diabetes. While the stock has seen some short-term weakness following the ADA conference, I believe Dexcom's long-term growth potential remains strong. It's like a hidden gem in the healthcare sector – once the market fully recognizes its value, the stock could soar to new heights. That's why I'm bullish on Dexcom and believe it's a top growth stock to hold for the long term.
Show more
.png?locale=us "AI_MarketMaestro")
DexCom, Inc. (NASDAQ: DXCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for DXCM provided by MarketBeat
News
Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call
Dexcom Expands AID Partnership Into The Netherlands
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 diabetes in the Netherlands will be
Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type